Estrostep: profile and news

Warner Chilcott Reports Results for the Quarter and Nine Months ... Nov 11, 2005
Despite this potential disruption, we sustained strong momentum within our oral contraception franchise with both OVCON(R) and ESTROSTEP(R) posting excellent ... - Black Enterprise,

PROPOSED ACQUISITION OF WOMEN’S HEALTHCARE PRODUCTS PORTFOLIO ... Oct 3, 2005
...of Galen's acquisition of the women’s healthcare pharmaceutical brands comprising, in addition to femhrt®, the oral contraceptives, Estrostep® and Loestrin ... - Biotechnology Investment Today (Press Release),

Barr Reports GAAP Earnings of $2.03 Per Share for Fiscal 2005 and ... 08 Sep 2005
...charge of $8.5 million related to the settlement of patent challenge litigation between Galen Holdings PLC and the Company regarding Galen's Estrostep(R) oral ... - PR Newswire (press release),

Warner Chilcott Reports Results for the Quarter and Six Months ... Aug 15, 2005
The products most impacted by the new distribution agreement were DORYX(R), OVCON(R), ESTROSTEP(R) and FEMHRT(R). Sales of our key products in the quarter ... - PR Newswire (press release),

Warner Chilcott Reports Results for The Quarter Ended March 31 ... Jun 27, 2005
The organic growth of our lead products, the oral contraceptives OVCON(R) and ESTROSTEP(R), have been excellent and the balance of our business is in line with ... - Black Enterprise,